Mingxu Ma Selected Research

NPI 2358

1/2020	Development of novel phenoxy-diketopiperazine-type plinabulin derivatives as potent antimicrotubule agents based on the co-crystal structure.
1/2019	Polymorphs, co-crystal structure and pharmacodynamics study of MBRI-001, a deuterium-substituted plinabulin derivative as a tubulin polymerization inhibitor.
1/2018	In vitro and in vivo pharmacokinetic and pharmacodynamic study of MBRI-001, a deuterium-substituted plinabulin derivative as a potent anti-cancer agent.
1/2018	Design, synthesis and biological evaluation of anti-pancreatic cancer activity of plinabulin derivatives based on the co-crystal structure.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Mingxu Ma Research Topics

Disease

3	Neoplasms (Cancer) 01/2022 - 01/2018
2	Lung Neoplasms (Lung Cancer) 01/2020 - 01/2019
1	Psychotic Disorders (Schizoaffective Disorder) 04/2022
1	Parkinson Disease (Parkinson's Disease) 04/2022
1	Ulcerative Colitis 07/2019
1	Inflammation (Inflammations) 07/2019
1	Pancreatic Neoplasms (Pancreatic Cancer) 01/2018

Drug/Important Bio-Agent (IBA)

4	NPI 2358IBA 01/2020 - 01/2018
2	Biological ProductsIBA 01/2020 - 01/2018
1	5-HT2A Serotonin Receptor (5 HT2A Receptor)IBA 04/2022
1	pimavanserinIBA 04/2022
1	abemaciclibIBA 01/2022
1	DiketopiperazinesIBA 01/2020
1	SodiumIBA 07/2019
1	Mesalamine (Mesalazine)FDA LinkGeneric 07/2019
1	myricetinIBA 07/2019
1	SaltsIBA 07/2019
1	Dextran SulfateIBA 07/2019
1	DeuteriumIBA 01/2018